India, 14th  November, 2025: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the second quarter ended September 30, 2025. The Board of Directors took record of these results at its meeting held in Mumbai today.

Key Financial Metrics

Commenting on the Q2 FY26 results, Dr. Vikas Gupta, CEO of Alkem, said,

“Q2 FY26 has been another strong quarter for us, marked by robust growth across India, the US, and key international markets. We also saw healthy traction in new product launches across markets. The GST revision is a positive step, and we adapted swiftly to ensure a seamless transition. Our improved gross margins and operating leverage have contributed to a stronger EBITDA profile. As we look ahead, we remain focused on accelerating growth and continue to strengthen our presence in key markets.”

Key highlights of Q2 FY26 financial performance

  • Total Revenue from Operations was INR 40,010 million, with YoY growth of 17.2%.
    India sales were INR 27,660 million, YoY growth of 12.4%.
    International sales were INR 11,890 million, with YoY growth of 29.5%.
    Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were INR 9,208 million, resulting in an EBITDA margin of 23.0% vs. 22.0% in Q2 FY25. EBITDA grew by 22.3% YoY.
    R&D expenses for Q2 FY26 were INR 1,302 million, or 3.3% of total revenue from operations, vs. INR 1,465 million in Q2 FY25 at 4.3% of total revenue from operations.
    Profit before tax was INR 8,958 million, YoY growth of 14.8%.
    Net Profit (after Minority Interest) was INR 7,651 million, YoY growth of 11.1%.

    According to IQVIA (SSA) data, for Q2 FY26:
    In the Acute segment, Alkem became the number one company in IPM this quarter.
    The Company registered a growth of 6.4% YoY, in line with the Indian Pharmaceutical Market (IPM), which also grew by 6.4%.

Domestic Business  Q2 FY26 Key Highlights

  • India sales were INR 27,660 million, YoY growth of 12.4%.

  • Domestic sales contributed 69.9% to total sales in Q2 FY26 vs. 72.8% in Q2 FY25.

  • As per IQVIA (SSA) data, the Company outperformed IPM in six therapies:

    • Anti-infectives: ~1.2X

    • Gastrointestinal: ~3.1X

    • VMN: ~2.5X

    • Pain: ~2.3X

    • Respiratory: ~1.5X

    • Derma: ~3.1X

International Business Q2 FY26 Key Highlights

  • International sales were INR 11,890 million, YoY growth of 29.5%.

  • US sales were INR 7,649 million, YoY growth of 28.0%.

  • US business contributed 19.3% to total sales in Q2 FY26.

  • Non-US sales were INR 4,241 million, YoY growth of 32.4%.

  • Non-US business contributed 10.7% to total sales in Q2 FY26.

  • During Q2 FY26, for the US market, the Company:

    • Filed 02 ANDAs

    • Received 01 ANDA tentative approval

    • Launched 04 products

  • As of September 30, 2025, the Company had filed:

    • 187 ANDAs

    • 02 NDAs

    • 01 BLA with the USFDA

    • Approvals received: 163 ANDAs (including 17 tentative approvals) and 02 NDAs